Immune Tolerance
Autoimmune diseases occur when the immune system mistakenly attacks the body’s own cells and organs, spanning a wide range of conditions such as Type 1 Diabetes, Multiple Sclerosis, and Inflammatory Bowel Disease. Today’s treatments mostly rely on broad immune suppression, which masks symptoms but doesn’t address the root cause.
INT Tolerizing Lipid Nanoparticle
A distinctive strength of our delivery technology is the ability to co-deliver different types of cargo, with effective targeting to immune cells. We are exploiting this unique technical capability to develop a therapeutic platform for a variety of immune diseases.
The INT Tolerizing LNPs contain both immune-modulating drug(s) and antigen within the same nanoparticle.
The antigen can be delivered as mRNA, DNA, protein or peptide, and is customized for the specific disease application.
Our immune tolerance platform enables precision therapies designed to restore true immune tolerance and target the underlying mechanism of autoimmunity.
Antigen-Specific Immune Tolerance
How does it work?
INT tolerizing LNPs carry both the self-antigen and immune-modulating drug(s) are taken up by dendritic cells.
While the self-antigen is processed and presented by dendritic cells, the immune-modulating drug sends inactivating signals to T cells, re-training them to not attack the self-antigen and coordinate a regulatory immune response.
The outcome is an antigen-specific immune tolerance effect as opposed to broad immunosuppression. With this approach, a person’s own cells and organs are protected while the immune system remains functional to fight infections.